Status:

COMPLETED

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

Lead Sponsor:

Cedars-Sinai Medical Center

Conditions:

Inflammatory Bowel Disease

Crohn Disease

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Patients with inflammatory bowel disease (IBD) will be assessed for immunologic response to pneumococcal vaccination. Patients with IBD meet criteria as outlined by the Centers for Disease Control (CD...

Eligibility Criteria

Inclusion

  • Males and females over the age of 18 with inflammatory bowel disease; healthy controls will be age- and sex-matched.
  • The patient must understand and voluntarily sign and informed consent document
  • A history of chronic (greater than 1 month) ulcerative colitis or Crohn's disease diagnosed and documented by the standard clinical, radiographic, endoscopic, and histopathologic criteria
  • (Group 1): Outpatients at CSMC IBD center with IBD who are on maintenance anti-TNF therapy with infliximab OR ADALIMUMAB plus concomitant immunomodulator therapy (with either 6MP, AZA, or MTX)
  • (Group 2): Outpatients at CSMC's IBD Center with documented IBD who are not on any immune-suppressive medications. Treatment with oral or topical 5-ASA products, antibiotics, or probiotics, are permitted.
  • (Group 3): Healthy volunteers without chronic illness, not on immune-suppressive medications.

Exclusion

  • Hypersensitivity to any component of the vaccine
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine (including thyroid), pulmonary, cardiac, infectious, neurologic or cerebral disease. Included are ongoing chronic active conditions such as chronic active hepatitis.
  • Patients who in the judgment of the investigator are unwilling or unable to comply with all the protocol-related assessments and procedures.
  • History of alcohol or other drug abuse within one year, or any conditions associated with poor compliance.
  • Patients in whom venipunctures are not feasible due to poor tolerability or lack of easy access.
  • Healthy volunteers or patients with a history of prior pneumococcal vaccination
  • Any condition which, in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study.

Key Trial Info

Start Date :

May 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2007

Estimated Enrollment :

69 Patients enrolled

Trial Details

Trial ID

NCT00829595

Start Date

May 1 2005

End Date

December 1 2007

Last Update

January 27 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cedars-Sinai Medical Center

Los Angeles, California, United States, 90048